In This Article:
-
Revenue: $25,000 for Q1 2025, compared to $35,000 in Q1 2024.
-
Deferred Revenue: $150,000 in Q1 2025, compared to nil in Q1 2024.
-
Loss from Operations: $4.8 million in Q1 2025, compared to $4.1 million in Q1 2024.
-
Net Loss: $5.3 million, or $0.64 per share, in Q1 2025, compared to $2.2 million, or $0.33 per share, in Q1 2024.
-
Cash Used in Operating Activities: $2.8 million in Q1 2025.
-
Cash, Cash Equivalents, and Marketable Securities: $9.1 million as of March 31, 2025.
-
Outstanding Debt: None as of the end of Q1 2025.
Release Date: May 14, 2025
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
BioRestorative Therapies Inc (NASDAQ:BRTX) achieved FDA fast track designation for their BRTX-100 program, facilitating development and review processes.
-
The company reported no serious adverse events in their ongoing Phase II study for BRTX-100, indicating a positive safety profile.
-
Preliminary data from the BRTX-100 trial shows promising trends in pain reduction and functional improvement.
-
BioRestorative Therapies Inc (NASDAQ:BRTX) ended the quarter with a strong financial position, holding $9.1 million in cash, cash equivalents, and marketable securities with no outstanding debt.
-
The company has expanded its intellectual property portfolio, enhancing protection for its ThermoStem program targeting obesity and metabolic disorders.
Negative Points
-
BioRestorative Therapies Inc (NASDAQ:BRTX) reported a decrease in quarterly revenues from $35,000 in Q1 2024 to $25,000 in Q1 2025.
-
The company's net loss increased significantly to $5.3 million in Q1 2025 from $2.2 million in Q1 2024.
-
Enrollment challenges persist due to strict criteria for the BRTX-100 trial, although new recruitment strategies are being implemented.
-
There is uncertainty regarding the potential interim analysis of the BRTX-100 trial, which could impact the trial's progression.
-
The company is still in discussions for a potential license agreement for its ThermoStem program, with no assurance of reaching a mutually acceptable agreement.
Q & A Highlights
Q: You mentioned a preliminary endpoint of greater than or equal to 30% improvement. Is there a possibility that this endpoint will change to greater than or equal to 50%? A: Francisco Silva, Vice President of Research & Development, clarified that the endpoint remains at a 30% improvement. The term "preliminary" refers to the fact that the primary endpoint is safety, not efficacy, as this is a first-in-man study.